Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer

Wei Guo(The University of Texas MD Anderson Cancer Center), Jié He(Zhejiang Marine Fisheries Research Institute), Lei Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Qilin Huai(Chinese Academy of Medical Sciences & Peking Union Medical College), Fengwei Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuemin Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Bolun Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cancer Immunology Immunotherapy
October 29, 2022
10.1007/s00262-022-03298-y
Cited by 14

Related Papers

TGF-β signaling in health, disease and therapeutics
|Signal Transduction and Targeted Therapy|2024|917
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2024|233
Mouse Embryonic Head as a Site for Hematopoietic Stem Cell Development
|Cell stem cell|2012|192
Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
|Annals of Oncology|2013|126
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
|Cell|2025|103